Other
Jun 2025CNBC reported that Formation Bio had not yet submitted a drug for regulatory approval, so clinical, regulatory, and execution risk remain material despite substantial funding and a growing pipeline.
SourceAI-powered drug development and clinical trials.
Company research
Public company, workplace, funding, and market signals
Updated Aug 2, 2026
Overview
Formation Bio is a privately held, AI-native pharmaceutical and biotechnology company, formerly TrialSpark. It acquires, licenses, and develops clinical-stage drug assets, using proprietary software, data, and AI to make drug development faster and more efficient.
Primary product
An AI-native drug-development platform and associated pharma operating model spanning asset sourcing, drug-selection intelligence, trial design, clinical-trial execution, and portfolio development. Named platform components include Atlas, Delphi, Forge, Apollo, ARK, and Muse.
Founded
2013
Headquarters
16 East 34th Street, Floor 10, New York, NY 10016, United States
Team size
100-200 (third-party estimates vary; one June 2026 estimate reported approximately 196 and another company-profile estimate reported 137)
Work style
Hybrid
Industry
Open Positions
22 jobs at Formation Bio
Director, People
On-sitePeopleNew York, NY; Boston, MA1w ago
On-site